Navigation Links
Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer

TOKYO, Dec. 17, 2010 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings Co., Ltd., announced today that the Committee for Medicinal Products for Human Use (CHMP), a division of the European Medicines Agency (EMA), has issued an opinion recommending approval of Teysuno™ (S-1), a novel oral anti-cancer agent, intended for the treatment of advanced gastric cancer in adults when given in combination with cisplatin. The Committee will now recommend that the European Commission (EC) grant marketing authorization for Teysuno, a decision that is normally issued within 67 days from adoption of a CHMP opinion.

"We are pleased with the CHMP's positive opinion on Teysuno. It is an important step toward a new treatment option for European adults living with gastric cancer," said Toru Usami, President, Taiho Pharmaceutical Co., Ltd. "The CHMP recommendation also represents the first regulatory milestone for Taiho outside of Japan and Asia. Teysuno is the first of what we hope will be many promising anti-cancer agents to be developed globally and made commercially available by Taiho."

A member of the fluoropyrimidine class of chemotherapeutic agents, Teysuno is a combination of three pharmacological compounds: tegafur, an antimetabolite agent that, after absorption, is converted into the anti-cancer agent fluorouracil (5-FU); gimeracil (5-chloro-2, 4-dihydroxypyridine, or CDHP), which decreases the degradation of 5-FU by the body; and oteracil (Oxo), which decreases 5-FU activation in the gastrointestinal tract. The Committee's recommendation was based in part on the results of the First-Line Advanced Gastric Cancer Study (FLAGS), the largest international Phase III trial ever conducted in patients with advanced gastric cancer.  

"In the FLAGS study, a Teysuno containing regimen was as effective as the comparator with a favorable safety profile," commented Fabio M. Benedetti, M.D., Chief Medical Officer of Taiho Pharma U.S.A., Inc.  "Availability of Teysuno in Europe will provide physicians with another option in the management of this very difficult to treat disease."

The CHMP, on the basis of quality, safety and efficacy data submitted, considers there to be a favourable benefit-to-risk balance for Teysuno and therefore recommends granting marketing authorization for the product. The CHMP recommendation requires formal approval by the EC for marketing of Teysuno in all European Union (EU) Member States, which is expected in early 2011.

Taiho is currently in discussions with potential marketing partners for Teysuno to ensure its timely and effective introduction to the European oncology community.

About Gastric Cancer

With an estimated 934,000 new cases per year (8.6% of all new cancer cases), gastric cancer is the fourth most common cancer worldwide, following lung, breast, and colorectal cancers.(1) It is the second most common cause of cancer-related death, accounting for an estimated 700,000 to 800,000 deaths annually.(1,2) Nearly 70% of new cases occur in developing countries; 42% of new cases occur in China alone.(1,2)

In Europe, gastric cancer is the seventh most common cancer and the sixth most common cause of cancer death, with an estimated annual mortality rate of 118,200.(3) In general, gastric cancer incidence rates are about twice as high among men as in women. The disease is difficult to cure unless it is diagnosed in its early stages. Unfortunately, because early gastric cancer causes few symptoms, the disease is not usually diagnosed until it has reached an advanced stage. In Europe, the five-year survival rate for gastric cancer is roughly 20% in men and 25% in women. Similarly, in the United States, the five-year survival rate for gastric cancer is 24%, though survival rates improve to 61% if the disease is detected early. However, less than one-quarter of gastric cancers are diagnosed at an early stage in the United States.(2) In contrast, the five-year survival rate exceeds 50% in Japan, where early gastric cancer is diagnosed relatively frequently due to mass screening efforts, which have been practiced since the 1960s.(1,2)

About Teysuno

Teysuno was designated an orphan medicinal product by the EMA in 2007 in recognition of its development specifically to treat the rare condition of gastric cancer. Since its initial approval in Japan in 1999, Teysuno has become a standard of care there for the treatment of gastric cancer. Teysuno is also approved for patients with gastric cancer in South Korea, China, Singapore and Taiwan. Teysuno was subsequently approved in Japan for six additional indications: for the treatment of colorectal, head and neck, non-small cell lung, metastatic breast, pancreatic and biliary tract cancers. To date, Teysuno has been used by more than 870,000 patients in Japan and Asia.

About Taiho Pharmaceutical Co., Ltd.

Taiho Pharmaceutical Co., Ltd. (Taiho) is a company engaged in discovery, development, manufacturing and marketing of pharmaceutical products, with headquarters in Tokyo, Japan. Taiho is one of the leading companies focused on oncology. More information is available at the company's website at

About Otsuka Holdings Co., Ltd.

The Otsuka Group is a global organization of 145 healthcare companies with nearly 39,000 employees. Otsuka Holdings Co., Ltd., is the Group's holding company. The main operating companies are Otsuka Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical Factory, Inc.; Taiho Pharmaceutical Co., Ltd.; Otsuka Warehouse Co., Ltd.; and Otsuka Chemical Co., Ltd. The Group operates in 23 countries and regions, conducting diversified businesses in four segments all connected by a focus on health: pharmaceuticals, nutraceuticals, consumer products, and other product areas. The Group's corporate philosophy of "Otsuka-people creating new products for better health worldwide" is supported by the corporate ethic of "JISSHO (Proof through Execution) and SOZOSEI (Creativity)." The Otsuka Group thus seeks to foster a culture and vitality appropriate to an enterprise involved with human health and to create innovative products that contribute to the health and wellness of people worldwide. For more information, please visit the company's website at

(1) Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.

(2) Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society, 2007.

(3) Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581–592.

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
2. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
3. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
4. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
7. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
8. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
9. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
10. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
11. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Post Your Comments:
(Date:10/8/2015)... 2015   Intrexon Corporation (NYSE: XON ... appointment of Joseph L. Vaillancourt as Senior ... Nimrodi who continues in his role as Head ... to generate sustainable, biologically based solutions to environmental problems. ... held a variety of key roles including, Vice President ...
(Date:10/8/2015)... IRVINE, Calif. , Oct. 8, 2015 ... announced its expansion into the North American market with ... Asia and Europe ... a pioneer of Target Enrichment methodology and sample preparation ... or NGS, facilitates both hereditary and somatic genetic testing ...
(Date:10/8/2015)... 2015  The ALS Association, in partnership with Prize4Life, ... to revolutionize communication technology solutions for people living with ... ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease ... the spinal cord. Eventually, people with ALS lose the ... leads to total paralysis and death within two to ...
(Date:10/8/2015)... , ... October 08, 2015 , ... ... into an exclusive license agreement to develop and commercialize intellectual property rights belonging ... original agreement from February 2009, and affords exclusive worldwide rights to intellectual property ...
Breaking Biology Technology:
... 9, 2011) The brain is a black box. ... much like the inner workings of a computer chip. ... economy of an assembly line, neural circuits are impenetrable ... Department of Neurobiology have developed a technique for unraveling ...
... of Standards and Technology (NIST),have demonstrated an ... mechanical component 1,000 times,more vigorously than ever ... a new tool for processing,information and potentially ... object at the,smallest possible, or quantum, scale. ...
... NEW YORK, March 9, 2011 ... is available in its catalogue: ... and Market Forecasts to 2017 ... Retinopathy Therapeutics - Pipeline Assessment and Market ...
Cached Biology Technology:
(Date:10/7/2015)... , October 8, 2015 ... revenues for Fingerprint Cards (FPC) during third quarter 2015 amounted ... guidance of around 860 MSEK that was communicated 20 August ... a further strengthened delivery capacity and a continued growing demand ... 2015 is estimated to be higher than during the third ...
(Date:10/5/2015)... ) releases the following ... NXTD ), a biometric authentication company focused on the ... ) releases the following market and company update ... authentication company focused on the growing mobile commerce market. ... ) releases the following market and company update ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court of ... another key ruling in favor of Crossmatch ™, ... fingerprint scanner company Suprema and its U.S. partner Mentalix ... a trade provision that declares it unlawful to engage ... infringing two of Crossmatch,s patents, the 5,900,993 patent and ...
Breaking Biology News(10 mins):
... The Proceedings of the National Academy of Science ... Medicine generated a mouse model exhibiting reduced inflammation. ... transcription factor LITAF (Lipopolysaccharide [LPS]-Induced TNF-Alpha Factor) controls ... better known and studied NF-kB transcriptional regulator. ...
... for insects and other small terrestrial animals by firing ... the water's surface. These water shots were once thought ... discovered new levels of sophistication in the archerfish's hunting ... behavior has evolved. The findings are reported by Thomas ...
... at the University of Rochester may have answered one ... our neurons, which are responsible for our crystal-clear thoughts, ... the November issue of Nature Neuroscience, the Rochester study ... "noisy," signals to represent the ambiguities of the real ...
Cached Biology News:
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
... imported for data analysis , Automatic grid, subgrid ... template assignment , ... Extensive background and signal options to optimize, ... results , ...
... DNA Gel Stain combo offers these benefits: ... products separately Offers a ... Eliminates risks to yourself, the environment ... from 100 bp to >30 kb. UltraPure Agarose is ...
... stocks contained in standard 96-well microtiter plates. ... approximately 5,000 clones per plate. After positive ... the corresponding subplate is screened with a ... well(s). Cells from a positive well are ...
Biology Products: